(Washington, DC, January 20, 2012)—National Pharmaceutical Council (NPC) Chief Science Officer Robert W. Dubois, MD, PhD, today debuted a column, “From Methods to Policy,” in the new peer-reviewed, bimonthly publication, Journal of Comparative Effectiveness Research. Dr. Dubois also serves as an associate editor for the Journal.
In his first column, Dr. Dubois outlines “the intended and unintended consequences of CER,” as a way to spur further dialogue about the shape CER takes and how it ultimately impacts health care. In coming issues, Dr. Dubois’ column will take a closer look at some of the challenges related to conducting, translating and disseminating CER.
“CER has great potential to improve medical decision-making and as a result our overall health. However, the detail of how we implement and use CER is critical to achieving this goal,” wrote Dr. Dubois. “The idea of this column is to maintain a proper focus on the progress of CER as a tool for better health care, and where appropriate, shed light on the times when the CER debate goes in the wrong direction.”
The Journal is published by Future Medicine Ltd., based in North London, UK. Selected content from the launch issue can be viewed at http://www.futuremedicine.com/toc/cer/1/1. To receive a free 30-day online trial to evaluate the Journal’s content, please contact info@futuremedicine.com, with PRESSCER in the subject line.
About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research, development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.
###